Although osimertinib has been established as the preferred frontline TKI in EGFR mutant NSCLC, the aforementioned crossover seems to be beneficial to the comparator group in terms of OS (31.8 months) based on an indirect comparison with previous clinical trials of first- and second-generation TKIs that have revealed a median OS between 18 and 28 months [23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.